Achieve the earliest detection of progression to CNV with the ForeseeHome™ AMD Monitoring Program.
ForeseeHome can detect changes in metamorphopsia, often before the patient notices any visual symptoms, providing important early indications of the possible development of wet AMD. Detection of wet AMD when the patient is asymptomatic, with excellent visual acuity and small lesion size, provides the opportunity for the most effective treatment outcome.
The ForeseeHome AMD Monitoring Program can help you protect your patients’ vision and protect their quality of life.
FDA Indication for Use
ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation. ForeseeHome is not intended to diagnose; diagnosis is the responsibility of the prescribing eye-care professional.